Triple-negative breast cancer (TNBC), which lacks hormone receptors and human epidermal growth factor receptors 2 (HER-2), accounts for 15 to 20 percent of breast cancer (BC) subtypes [1]. Here, ERBB2 is linked to breast carcinoma.